ASCO 2025: First phase 2 RCT of CAR T-cell therapy in solid tumours finds promising results
Patients with advanced gastric or gastro-oesophageal junction (GEJ) cancer treated with CAR T-cell therapy lived…
Browsing: Featured
ASCO 2025 Special Part 1! S3E4 The Oncology Journal Club
Welcome to Part 1 of the 2025 ASCO ASM Special of The Oncology Journal Club! Our Host Craig Underhill is joined by Dr Kate Clarke and Professor Christopher Jackson to unpack practice changing presentations from Chicago.
Global warming may raise women’s cancer risk
Scientists investigating the impact of climate change on women’s health have found that increased heat…
ASCO 2025: Adding niraparib to standard treatment may slow cancer growth for some patients with mCSPC
Results from the international phase 3 AMPLTUDE clinical trial found that adding niraparib to abiraterone…
ASCO 2025: Addition of lurbinectedin to first-line maintenance treatment for small cell lung cancer prolongs survival, according to phase 3 trial
Small cell lung cancer (SCLC) accounts for approximately 15% of lung cancers, and most patients…
ASCO 2025: Dual-target CAR T-cell therapy slows growth of aggressive brain cancer
A dual-target CAR T cell therapy approach shows promise for slowing tumour growth in glioblastoma. Tumours became…
ASCO 2025: Rusfertide shows promise for polycythemia vera treatment
Results from the Phase 3, randomised, placebo-controlled VERIFY study evaluating rusfertide in patients with polycythemia…
ASCO 2025: Switch to camizestrant after liquid biopsy detection of breast cancer recurrence improves outcomes
A large prospective, randomised clinical trial in patients with advanced breast cancer has found that…
ASCO 2025: Exercise programme may lower risk of recurrence and death for some colon cancer survivors
New study results show that a structured exercise programme following surgery and adjuvant chemotherapy reduced…
ASCO 2025: Perioperative treatment with durvalumab and FLOT chemo can reduce risk of recurrence for some gastric cancers
Results from an international phase 3 clinical trial found that treating stage II, III, and…